Iron deficiency anemia (IDA) remains one of the most widespread hematological disorders worldwide and represents a major public health concern affecting children, women of reproductive age, pregnant women, and elderly populations. According to the World Health Organization, iron deficiency accounts for nearly 50% of all anemia cases globally [1]. The modern approach to the treatment of IDA involves the use of highly bioavailable ferropreparations with improved tolerability and pharmacokinetic properties. This article analyzes the effectiveness of contemporary oral and parenteral iron preparations, including ferrous sulfate, ferrous fumarate, ferric polymaltose complex, iron sucrose, ferric carboxymaltose, and iron isomaltoside. The study evaluates therapeutic efficacy, safety profile, gastrointestinal tolerance, absorption characteristics, hemoglobin recovery rate, and ferritin restoration. Clinical studies demonstrate that modern ferropreparations significantly improve hematological indicators while reducing adverse reactions and improving patient compliance. Intravenous preparations exhibit rapid correction of severe anemia and iron stores in patients with chronic diseases, inflammatory bowel disease, chronic kidney disease, and pregnancy-associated anemia. The article highlights evidence-based recommendations for selecting appropriate ferrotherapy depending on patient characteristics and severity of iron deficiency.

Iron deficiency anemia, ferropreparations, ferric carboxymaltose, iron sucrose, oral iron therapy, intravenous iron, ferritin, hemoglobin, ferrous sulfate, ferric polymaltose, bioavailability, hematology.

World Health Organization. Worldwide prevalence of anaemia 1993–2005. Geneva: WHO Press; 2008. pp. 1–40.

Camaschella C. Iron-deficiency anemia. New England Journal of Medicine. 2015;372(19):1832–1843. pp. 1832–1835.

Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harbor Perspectives in Medicine. 2013;3(7):a011866. pp. 1–13.

Breymann C. Iron deficiency anemia in pregnancy. Seminars in Hematology. 2015;52(4):339–347. pp. 339–344.

Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. American Family Physician. 2013;87(2):98–104. pp. 98–101.

Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects. PLoS One. 2015;10(2):e0117383. pp. 1–12.

Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. American Journal of Hematology. 2016;91(1):31–38. pp. 31–35.

Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. On the relative safety of parenteral iron formulations. Nephrology Dialysis Transplantation. 2004;19(6):1571–1575. pp. 1571–1573.

Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. Expert Opinion on Drug Safety. 2018;17(2):149–159. pp. 149–155.

Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. Journal of Internal Medicine. 2020;287(2):153–170. pp. 153–160.

Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of iron deficiency in pregnancy. British Journal of Haematology. 2020;188(6):819–830. pp. 819–825.

DeLoughery TG. Iron deficiency anemia. Medical Clinics of North America. 2017;101(2):319–332. pp. 319–325.

Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements. Current Medical Research and Opinion. 2013;29(4):291–303. pp. 291–297.

Elli L, Ferretti F, Branchi F, et al. Sucrosomial iron supplementation in anemic patients. Nutrients. 2018;10(10):1349. pp. 1–11.

Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor trial: ferric carboxymaltose in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–853. pp. 846–850.

Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous iron sucrose. Nephrology Dialysis Transplantation. 2011;26(5):1599–1607. pp. 1599–1603.

Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside. Clinical Kidney Journal. 2016;9(1):33–39. pp. 33–37.

Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations. Mayo Clinic Proceedings. 2015;90(1):12–23. pp. 12–18.

Stoffel NU, Zeder C, Brittenham GM, et al. Iron absorption from supplements is greater with alternate day dosing. The Lancet Haematology. 2017;4(11):e524–e533. pp. e524–e530.

López A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. The Lancet. 2016;387(10021):907–916. pp. 907–912.

Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochimica et Biophysica Acta. 2012;1823(9):1434–1443. pp. 1434–1438.

Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease. Kidney International Supplements. 2016;6(3):292–312. pp. 292–300.

Rahman MM, Abe SK, Rahman MS, et al. Maternal anemia and adverse birth outcomes. American Journal of Clinical Nutrition. 2016;103(2):495–504. pp. 495–500.

Froessler B, Collingwood J, Hodyl NA, et al. Intravenous ferric carboxymaltose for anemia in pregnancy. Transfusion. 2014;54(12):3061–3068. pp. 3061–3065.

Gozzelino R, Arosio P. Iron homeostasis in health and disease. International Journal of Molecular Sciences. 2016;17(1):130. pp. 1–15.

Crielaard BJ, Rivella S. β-thalassemia and iron metabolism. Current Opinion in Hematology. 2014;21(3):187–194. pp. 187–192.